Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time

Hum Reprod. 2007 Dec;22(12):3084-91. doi: 10.1093/humrep/dem238. Epub 2007 Oct 5.

Abstract

Background: Levonorgestrel-releasing intrauterine system (LNG-IUS), although inserted to reduce heavy menstruation, causes irregular early transient bleeding. The objective of the study was to document quantitative changes in endometrial vessels of short- (< or =3 months) and long-term (> or =12 months) LNG users. The area, density and maturation of endometrial vessels were quantified in 19 endometrial biopsies of women with LNG-IUS and in 10 normally ovulating patients during mid-luteal phase.

Methods: Vessel maturation was evaluated by double immunostaining using anti-von Willebrand factor (endothelial cell marker) and anti-alpha Smooth Muscle Actin (vascular smooth muscle cells) antibodies. Vessel area, number and density were quantified with a novel computer-assisted image analysis system.

Results: Endometrium exposed to LNG-IUS for 1-3 months displayed a 11.5-fold increase in small naked vessel number. The partially mature vessel (alphaSMA partially positive) number increased six times. After long-term LNG-IUS treatment, the immature and partially mature vessel number remained four times higher than in the control group. Vessel area and density also increased dramatically in a time-dependent pattern with LNG-IUS use.

Conclusions: Levonorgestrel affects blood vessel number, area, density and maturation in a time-dependent pattern that may explain the early transient increase in breakthrough bleeding with the LNG-IUS.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Adult
  • Biopsy
  • Contraceptive Agents, Female / adverse effects*
  • Endometrium / blood supply
  • Endometrium / drug effects*
  • Endometrium / pathology
  • Female
  • Humans
  • Levonorgestrel / adverse effects*
  • Menstruation Disturbances / drug therapy*
  • Menstruation Disturbances / pathology
  • Neovascularization, Pathologic / chemically induced*
  • Neovascularization, Pathologic / metabolism
  • Neovascularization, Pathologic / pathology
  • Prospective Studies
  • Stromal Cells / drug effects
  • Stromal Cells / pathology
  • Time Factors
  • von Willebrand Factor / metabolism

Substances

  • Actins
  • Contraceptive Agents, Female
  • von Willebrand Factor
  • Levonorgestrel